EFS
FIGURE 3 · Panel AUC_dose_1_quartiles
Panel AUC_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu-Qian Zhang, Cathy O'Brien, Gary J Doherty, Allen C Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou
Br J Clin Pharmacol 92(3) 980-996
AIMS: In the AEGEAN study, perioperative durvalumab plus platinum-based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non-small-cell lung cancer (NSCLC) demonstrated a favourable benefit-risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure-response (ER) relationships of durvalumab in patients with resectable NSCLC. METHODS: The durvalumab PopPK model was updated by integrating PK data from the AEGEAN study. Individual exposure metrics were derived from empirical Bayes estimates for ER analyses relating to safety (adverse events [AEs]) and efficacy (pathological complete response [pCR] and event-free survival [EFS]). RESULTS: A two-compartment model with a time-dependent clearance adequately characterized durvalumab PK data. The typical parameter estimates clearance, central and peripheral volume of distribution were 0.285 L/day (relative standard error: 1.68%), 3.42 L (0.962%) and 2.30 L (2.09%), respectively. All identified covariates caused ≤21% of change on durvalumab PK parameters, indicating no meaningful impact on durvalumab exposure. At the plateaued dose level of durvalumab 1500 mg, a flat relationship was observed between durvalumab PK exposure and EFS, confirmed by Cox proportional hazards analysis, and pCR, confirmed by logistic regression analysis. Logistic regression analysis indicated that no clinically relevant relationships were observed between durvalumab PK exposure and safety endpoints, including grade ≥3 treatment-related AEs, grade ≥3 treatment-related AEs of special interest, and AEs leading to treatment discontinuation. CONCLUSIONS: These results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses.
1 个 Figure · 6 个 KM 面板
FIGURE 3 EFS Kaplan–Meier plots for durvalumab exposure metrics by quartiles at dose 1 (A) and steady state (B). Abbreviations: AUC, area under the serum concentration–time curve; AUC, dose 1, AUC from time 0 to the end of dosing interval following the first dose; AUC ss , AUC at steady state; C max , maximum concentration; C max , dose 1, C max following the first dose; C max ,ss, C max at steady state; C min , trough concentration; C min , dose 1, C min following the first dosing cycle; C min ,ss, C min at steady state; CI, confidence interval; EFS, event‐free survival; QX, quartile X.
FIGURE 3 · Panel AUC_dose_1_quartiles
Panel AUC_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel Cmax_dose_1_quartiles
Panel Cmax_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel Cmin_dose_1_quartiles
Panel Cmin_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel AUC_steady_state_quartiles
Panel AUC_steady_state_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel Cmax_steady_state_quartiles
Panel Cmax_steady_state_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel Cmin_steady_state_quartiles
Panel Cmin_steady_state_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。